GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (NAS:CTIC) » Definitions » Cash Flow from Financing

CTI BioPharma (CTI BioPharma) Cash Flow from Financing : $68.22 Mil (TTM As of Mar. 2023)


View and export this data going back to 1997. Start your Free Trial

What is CTI BioPharma Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2023, CTI BioPharma paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $6.50 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $3.13 Mil on other financial activities. In all, CTI BioPharma earned $9.63 Mil on financial activities for the three months ended in Mar. 2023.


CTI BioPharma Cash Flow from Financing Historical Data

The historical data trend for CTI BioPharma's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Cash Flow from Financing Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.49 -5.61 61.07 97.94 120.02

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.43 44.22 1.02 13.35 9.63

CTI BioPharma Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

CTI BioPharma's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

CTI BioPharma's Cash from Financing for the quarter that ended in Mar. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $68.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CTI BioPharma  (NAS:CTIC) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

CTI BioPharma's issuance of stock for the three months ended in Mar. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

CTI BioPharma's repurchase of stock for the three months ended in Mar. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

CTI BioPharma's net issuance of debt for the three months ended in Mar. 2023 was $6.50 Mil. CTI BioPharma received $6.50 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

CTI BioPharma's net issuance of preferred for the three months ended in Mar. 2023 was $0.00 Mil. CTI BioPharma paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

CTI BioPharma's cash flow for dividends for the three months ended in Mar. 2023 was $0.00 Mil. CTI BioPharma received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

CTI BioPharma's other financing for the three months ended in Mar. 2023 was $3.13 Mil. CTI BioPharma received $3.13 Mil on other financial activities.


CTI BioPharma Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


CTI BioPharma (CTI BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
Executives
James K Fong officer: EVP & Chief Commercial Officer C/O CTI BIOPHARMA CORP, 3101 WESTERN AVENUE, SUITE 800, SEATTLE WA 98121
Adam R Craig director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
David Kirske officer: EVP, Chief Financial Officer C/O CTI BIOPHARMA CORP., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Matthew D Perry director ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Laurent Fischer director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
David Ross Parkinson director C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Richard L Love director
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104